Catalyst
Slingshot members are tracking this event:
GOYA study did not meet its primary endpoint of improvement in progression-free survival with Gazyva plus CHOP chemotherapy versus Rituxan plus CHOP chemotherapy
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| RHHBY |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 17, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Diffuse Large B-cell Lymphoma, Gazyva, Phase Iii Study, Phase Iii Goya Study, Rituxan, Progression-free Survival, Monoclonal Antibody, Cd20, Untreated Follicular Lymphoma, Chronic Lymphocytic Leukemia
